These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12420237)

  • 1. Methods for the monitoring of direct thrombin inhibitors.
    Hafner G; Roser M; Nauck M
    Semin Thromb Hemost; 2002 Oct; 28(5):425-30. PubMed ID: 12420237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical monitoring of hirudin and direct thrombin inhibitors.
    Nowak G
    Semin Thromb Hemost; 2001 Oct; 27(5):537-41. PubMed ID: 11668425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
    Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
    Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative studies on various assays for the laboratory evaluation of r-hirudin.
    Walenga JM; Hoppensteadt D; Koza M; Pifarre R; Fareed J
    Semin Thromb Hemost; 1991 Apr; 17(2):103-12. PubMed ID: 1771408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples.
    Lind SE; Boyle ME; Fisher S; Ishimoto J; Trujillo TC; Kiser TH
    Am J Clin Pathol; 2014 May; 141(5):665-74. PubMed ID: 24713737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring the new antithrombotic drugs.
    Walenga JM; Hoppensteadt DA
    Semin Thromb Hemost; 2004 Dec; 30(6):683-95. PubMed ID: 15630675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Follow-up of the treatment by direct thrombin inhibitors: activated partial thromboplastin time or ecarin clotting time].
    Kher A; Gouin I; Samama MM
    Ann Biol Clin (Paris); 2000; 58(5):575-9. PubMed ID: 11022100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful?
    Curvers J; van de Kerkhof D; Stroobants AK; van den Dool EJ; Scharnhorst V
    Am J Clin Pathol; 2012 Oct; 138(4):551-8. PubMed ID: 23010710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass--assessment of the whole blood ecarin clotting time.
    Pötzsch B; Madlener K; Seelig C; Riess CF; Greinacher A; Müller-Berghaus G
    Thromb Haemost; 1997 May; 77(5):920-5. PubMed ID: 9184403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R; Jacobs C
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
    Lindahl TL; Baghaei F; Blixter IF; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Hillarp A;
    Thromb Haemost; 2011 Feb; 105(2):371-8. PubMed ID: 21103660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time.
    Love JE; Ferrell C; Chandler WL
    Thromb Haemost; 2007 Jul; 98(1):234-42. PubMed ID: 17598018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified plasma-based ecarin clotting time assay for monitoring of recombinant hirudin during cardiac surgery.
    Choi TS; Khan AI; Greilich PE; Kroll MH
    Am J Clin Pathol; 2006 Feb; 125(2):290-5. PubMed ID: 16393689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing.
    Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT
    Ann Pharmacother; 2004 Sep; 38(9):1383-8. PubMed ID: 15238620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory assays for the evaluation of recombinant hirudin.
    Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
    Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The uncalibrated prothrombinase-induced clotting time test. Equally convenient but more precise than the aPTT for monitoring of unfractionated heparin.
    Korte W; Jovic R; Hollenstein M; Degiacomi P; Gautschi M; Ferrández A
    Hamostaseologie; 2010 Nov; 30(4):212-6. PubMed ID: 21057708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays.
    Wakui M; Fujimori Y; Nakamura S; Kondo Y; Kuroda Y; Oka S; Nakagawa T; Katagiri H; Murata M
    J Clin Pathol; 2019 Dec; 72(12):817-824. PubMed ID: 31366633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors.
    Van Cott EM; Roberts AJ; Dager WE
    Semin Thromb Hemost; 2017 Apr; 43(3):270-276. PubMed ID: 28052306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay.
    Pötzsch B; Hund S; Madlener K; Unkrig C; Müller-Berghaus G
    Thromb Res; 1997 Jun; 86(5):373-83. PubMed ID: 9211628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of three methods for measuring PEG-hirudin in blood.
    Hoffmann JJ; Janssen WC
    Blood Coagul Fibrinolysis; 2001 Oct; 12(7):577-81. PubMed ID: 11685047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.